Immutep Limited Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Immutep Limited following a significant decline in stock price after the discontinuation of a clinical trial [1][3][4]. Group 1: Investigation Details - The investigation focuses on whether Immutep's executive officers may have violated federal securities laws, leading to investor losses [1][4]. - The Independent Data Monitoring Committee recommended discontinuation of Immutep's Phase III TACTI-004 clinical trial due to an interim futility analysis indicating the trial was unlikely to meet its primary endpoints [3]. Group 2: Stock Performance - Following the announcement of the trial discontinuation, Immutep's stock price plummeted approximately 85–90% in a single trading session [4]. Group 3: Legal Firm Background - Johnson Fistel, PLLP is a nationally recognized law firm specializing in shareholder rights and has recovered approximately $90,725,000 for clients in securities class action lawsuits [5][6].